Mauna Kea Technologies and TaeWoong Medical USA have announced an exclusive partnership aimed at expanding their commercial presence in the United States for pancreatic cyst management. The collaboration will combine Mauna Kea’s Cellvizio, a probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, with TaeWoong’s expertise in minimally invasive gastrointestinal diagnostic and therapeutic EUS-guided solutions.
The companies plan to offer what they describe as the first fully integrated "imaging-to-therapy" solution for pancreatic cystic lesions (PCLs) and related disorders. By merging Mauna Kea’s real-time cellular imaging with TaeWoong’s EUS-guided therapeutic instruments, the partnership aims to streamline clinical workflows, improve diagnostic accuracy, and enhance patient outcomes from diagnosis through treatment.
The new program, called “Pancreatic Cyst Imaging and Management Program – Powered by Cellvizio,” will feature real-time nCLE imaging during EUS procedures, advanced diagnostic and therapeutic tools from TaeWoong Medical, clinical training for care teams, and support throughout the patient management process. The companies expect these measures to reduce unnecessary surgeries by improving patient selection for therapy.
Sacha Loiseau, Ph.D., Chairman & CEO of Mauna Kea Technologies, stated: "The in vivo evaluation of cysts for patients at risk of pancreatic cancer has been a pillar of demand for Cellvizio, supported by proven clinical outcomes and the advocacy of key opinion leaders internationally. However, the scope of our US sales organization limits our commercial reach until now. Our partnership with TaeWoong Medical USA is expected to meaningfully expand Cellvizio’s U.S. footprint by integrating leading therapeutic products with Mauna Kea’s advanced diagnostic capabilities. Moreover, combining TaeWoong’s US commercial infrastructure with a unified value proposition should allow us to scale smarter together. We are thrilled with this alliance as it further validates that Cellvizio has earned the opportunity to be considered a standard of care in a critical clinical application."
Minsoo Seo, CEO of TaeWoong Medical USA added: “We are excited to join forces with Mauna Kea Technologies. Cellvizio’s needle-based microscopic technology is unmatched in its ability to provide real-time cellular-level insights, and its clinical value is recognized by leading centers across the country. Together, we can empower physicians with a complete diagnostic-to-therapeutic solution that elevates patient outcomes and sets a new standard for EUS-driven care.”
RM Global Partners LLC advised Mauna Kea Technologies on this transaction.
The press release also includes forward-looking statements regarding business strategies and future operations which are subject to risks detailed in Mauna Kea Technologies' 2024 Annual Report filed with French regulators on April 30, 2025.
